<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.113139</article-id><article-id pub-id-type="publisher-id">ACM-40888</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210300000_69440373.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  DNA甲基化与胃癌关系的研究进展
  Research Progress on the Relationship between DNA Methylation and Gastric Cancer
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>孙</surname><given-names>良旭</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郭</surname><given-names>安兵</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>艳青</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>彭</surname><given-names>利军</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>山东省临沂市人民医院，山东 临沂</addr-line></aff><aff id="aff2"><addr-line>山东第一医科大学(山东省医学科学院)，山东 济南；山东省临沂市人民医院，山东 临沂</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>03</month><year>2021</year></pub-date><volume>11</volume><issue>03</issue><fpage>965</fpage><lpage>973</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    胃癌是最常见的恶性肿瘤之一。我国胃癌发病率与死亡率依然较高，而很多胃癌患者初次发现时便已处于进展期，情况不容乐观，故对胃癌发生发展相关机制的深入研究并早日攻克胃癌显得尤为迫切。胃癌发病机制目前还没有完全清楚，目前主要认为是环境与饮食、感染、遗传与表观遗传协同作用导致，而DNA甲基化为表观遗传学中重要机制之一，近年来逐渐成为热点。DNA甲基化与胃癌的发生发展关系密切。DNA甲基化在胃癌发病过程中所起作用以及临床应用深入探索可能会对未来攻克胃癌产生深远意义。文章主要对近年来关于DNA甲基化与胃癌致病机制以及临床应用方面相关研究作出综述。
    Gastric cancer is one of the most common malignant tumors. The incidence and mortality of gastric cancer in my country are still high, and many patients with gastric cancer are already in the advanced stage when they are first discovered. The situation is not optimistic. Therefore, it is particularly urgent to study the related mechanisms of gastric cancer occurrence and development as soon as possible. The pathogenesis of gastric cancer is not yet fully understood. At present, it is mainly considered to be caused by the synergy of environment and diet, infection, genetics and epigenetics. DNA methylation is one of the important mechanisms in epigenetics and has gradually become a hot spot in recent years. DNA methylation is closely related to the occurrence and development of gastric cancer. The role of DNA methylation in the pathogenesis of gastric cancer and the in-depth exploration of its clinical application may have far-reaching significance in the future to overcome gastric cancer. This article mainly summarizes the research on DNA methylation and gastric cancer pathogenesis and clinical application in recent years. 
  
 
</p></abstract><kwd-group><kwd>DNA甲基化，胃癌，表观遗传学，DNA甲基转移酶, DNA Methylation</kwd><kwd> Gastric Cancer</kwd><kwd> Epigenetics</kwd><kwd> DNA Methyltransferase</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>胃癌是最常见的恶性肿瘤之一。我国胃癌发病率与死亡率依然较高，而很多胃癌患者初次发现时便已处于进展期，情况不容乐观，故对胃癌发生发展相关机制的深入研究并早日攻克胃癌显得尤为迫切。胃癌发病机制目前还没有完全清楚，目前主要认为是环境与饮食、感染、遗传与表观遗传协同作用导致，而DNA甲基化为表观遗传学中重要机制之一，近年来逐渐成为热点。DNA甲基化与胃癌的发生发展关系密切。DNA甲基化在胃癌发病过程中所起作用以及临床应用深入探索可能会对未来攻克胃癌产生深远意义。文章主要对近年来关于DNA甲基化与胃癌致病机制以及临床应用方面相关研究作出综述。</p></sec><sec id="s2"><title>关键词</title><p>DNA甲基化，胃癌，表观遗传学，DNA甲基转移酶</p></sec><sec id="s3"><title>Research Progress on the Relationship between DNA Methylation and Gastric Cancer<sup> </sup></title><p>Liangxu Sun<sup>1,2*</sup>, Anbing Guo<sup>2</sup>, Yanqing Zhang<sup>2</sup>, Lijun Peng<sup>2#</sup></p><p><sup>1</sup>ShandongFirst Medical University (Shandong Academy of Medical Sciences), Jinan Shandong</p><p><sup>2</sup>ShandongLinyiPeople’s Hospital, Linyi Shandong</p><p><img src="//html.hanspub.org/file/22-1572003x4_hanspub.png" /></p><p>Received: Feb. 11<sup>th</sup>, 2021; accepted: Mar. 1<sup>st</sup>, 2021; published: Mar. 12<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/22-1572003x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Gastric cancer is one of the most common malignant tumors. The incidence and mortality of gastric cancer in my country are still high, and many patients with gastric cancer are already in the advanced stage when they are first discovered. The situation is not optimistic. Therefore, it is particularly urgent to study the related mechanisms of gastric cancer occurrence and development as soon as possible. The pathogenesis of gastric cancer is not yet fully understood. At present, it is mainly considered to be caused by the synergy of environment and diet, infection, genetics and epigenetics. DNA methylation is one of the important mechanisms in epigenetics and has gradually become a hot spot in recent years. DNA methylation is closely related to the occurrence and development of gastric cancer. The role of DNA methylation in the pathogenesis of gastric cancer and the in-depth exploration of its clinical application may have far-reaching significance in the future to overcome gastric cancer. This article mainly summarizes the research on DNA methylation and gastric cancer pathogenesis and clinical application in recent years.</p><p>Keywords:DNA Methylation, Gastric Cancer, Epigenetics, DNA Methyltransferase</p><disp-formula id="hanspub.40888-formula24"><graphic xlink:href="//html.hanspub.org/file/22-1572003x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/22-1572003x8_hanspub.png" /> <img src="//html.hanspub.org/file/22-1572003x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>胃癌(gastric cancer, GC)是最常见的恶性肿瘤之一，其发病率与死亡率均位于全世界癌症前5位 [<xref ref-type="bibr" rid="hanspub.40888-ref1">1</xref>]。东亚地区尤其我国更是胃癌的高发地区，情况不容乐观。目前胃癌的明确病因与发病机制还没有充分研究清楚。目前主要认为是感染因素、环境与饮食因素、遗传因素(遗传学、表观遗传学)协同作用的结果。近几年关于表观遗传学与胃癌发生发展关系的探索已经成为热点，而DNA甲基化(DNA methylation)是其重要机制之一，目前很多研究表明DNA甲基化和胃癌发生发展关系密切。并且在胃癌早期诊断、药物治疗以及判断预后等临床一线应用方面DNA甲基化可能会有很大意义。文章主要对近年来关于DNA甲基化与胃癌致病机制以及临床应用方面相关研究作出综述。</p></sec><sec id="s6"><title>2. DNA甲基化在胃癌发生发展中作用机制研究现状</title><sec id="s6_1"><title>2.1. 表观遗传学</title><p>表观遗传学：由英国生物学家Conrad Waddington 1942年在Endeavour第一次提出。近几年随着分子生物学、基因组学的进步，逐渐成为热点，并且迅速发展的一门遗传学分支学科 [<xref ref-type="bibr" rid="hanspub.40888-ref2">2</xref>]。主要指DNA序列未出现改变，遗传表达却发生可遗传改变。其修饰可于多个水平调控遗传表达，主要包括：遗传印记、染色质重塑、DNA甲基化、组蛋白修饰、非编码RNA等。其在细胞生长发育、增殖分化以及肿瘤发病等方面有重要作用。</p></sec><sec id="s6_2"><title>2.2. DNA甲基化研究现状</title><p>DNA甲基化为表观遗传学现象之一，为真核生物在染色质水平控制转录重要机制，这种改变可遗传、可逆。由DNA甲基转移酶(DNA methyltransferase, DNMT)作用，把甲基供体S-腺苷甲硫氨酸(S-Adenosyl methyonine, SAM)的甲基转到相应碱基上的过程。一般主要转移至真核基因组胞嘧啶第五位C原子，而成为5-甲基胞嘧啶，并且以序列GC甲基化更为常见，如在大多数基因启动子区都存在的CpG岛 [<xref ref-type="bibr" rid="hanspub.40888-ref3">3</xref>]。</p><p>正常的甲基化状态可对于细胞生长、发育、增殖、分化等有重要的作用，而异常的甲基化状态会使得细胞周期、DNA损伤修复、基因转录等发生异常，导致肿瘤的发生。</p><p>高甲基化：未出现甲基化的正常DNA位点被甲基化。正常状态启动子区域CpG岛呈现非甲基化，染色质松散，利于基因转录。而高甲基化后，染色质变紧密，进而干扰转录 [<xref ref-type="bibr" rid="hanspub.40888-ref4">4</xref>]。真核生物启动子区域CpG岛甲基化修饰对于调节转录至关重要，甲基化水平与基因的表达呈负相关。DNA损伤修复基因、抑癌基因等CPG岛高甲基化可致其转录不表达或者低表达，出现抑癌基因失活、相关DNA损伤后无法修复，从而致癌 [<xref ref-type="bibr" rid="hanspub.40888-ref5">5</xref>]。</p><p>低甲基化：已有甲基化正常DNA位点被去甲基化。可致原本表达沉默的相关基因(原癌基因多见)被激活、染色质的结构发生改变，可致基因组突变，遗传不稳定性上升，最终可导致癌症。并且相关研究发现，DNA低甲基化与肿瘤发生、进展与转移高度相关 [<xref ref-type="bibr" rid="hanspub.40888-ref6">6</xref>]。而局部DNA高甲基化与全基因组DNA低甲基化通常可出现在同一肿瘤中 [<xref ref-type="bibr" rid="hanspub.40888-ref7">7</xref>]。相关研究表明胃癌与甲基化的失衡密切相关，研究结果显示胃炎组织、癌旁正常组织均可发生全基因组的低甲基化 [<xref ref-type="bibr" rid="hanspub.40888-ref8">8</xref>]。</p><p>基因甲基化主要通过下面的途径导致肿瘤形成与进展：1) 影响染色质结构的稳定。2) 影响癌基因或抑癌基因正常表达。3) 影响细胞周期：干扰细胞分裂增殖或凋亡。4) 影响信号转导通路。5) 影响细胞侵袭和转移。</p><p>目前普遍认为肿瘤发生过程中启动子区异常甲基化与DNA甲基转移酶高表达有关 [<xref ref-type="bibr" rid="hanspub.40888-ref9">9</xref>]。目前已经知道的DNMT家族中能够发挥明显作用的有三种：DNMT1、DNMT3a、DNMT3b。DNMT1的作用是维持甲基化状态的稳定，使得已有的甲基化状态不发生变化。使其可以继续特异性辨别子代DNA中相对应的位点，复制时催化其反应过程 [<xref ref-type="bibr" rid="hanspub.40888-ref10">10</xref>]。DNMT3a、DNMT3b的作用为催化未发生甲基化的DNA出现新甲基化。可参与机体在各种环境应答时动态甲基化过程 [<xref ref-type="bibr" rid="hanspub.40888-ref11">11</xref>]。目前主要认为CpG岛甲基化导致转录抑制的机制主要为：1) 直接影响了转录因子和启动子区域特异性识别位点结合。2) 甲基化CpG结合蛋白(methyl-CpG-binding proteins)与异常相关调控序列结合，影响转录起始复合物形成，从而抑制相关基因表达 [<xref ref-type="bibr" rid="hanspub.40888-ref12">12</xref>]。</p></sec><sec id="s6_3"><title>2.3. 胃癌相关基因的甲基化</title><p>异常甲基化和胃癌关系十分紧密。包括抑癌基因：细胞周期相关基因(P16、PAX5、p15等)、细胞凋亡相关基因(DAPK、RNF180、Bcl-2等)、信号转导相关基因(RUNX3、RASSF1A、PTEN、APC等)、细胞黏附和转移相关基因(CDH1、TIMP1、TIMP3等)，原癌基因(Ras、c-myc等)以及DNA修复基因(hMLH1、XRCC1、GSTP1、MGLT等)等多种基因。下面主要介绍几个研究较多的胃癌相关基因研究情况：</p><p>P16 (亦称多肿瘤抑制因子1，multiple tumor spppressor1，MTS1)基因：位于染色体9P21区，是细胞周期中的基本调节因子。是肿瘤抑制基因，其表达产物参与细胞周期调控，负性调节细胞增殖和分裂。主要参与CDK6-PRb-E2F/cyclinD1-CDK4环路的负性调节。P16表达产物P16蛋白通过抑制细胞分裂周期关键酶之一CDK4正常功能，进而影响与细胞周期素结合，从而控制G1-S的转换，最终阻止细胞进入S期。一旦P16基因发生失活，就无法抑制CDK4，细胞发生无限制增殖，导致恶性肿瘤发生，而启动子区甲基化为导致其失活重要因素之一 [<xref ref-type="bibr" rid="hanspub.40888-ref13">13</xref>]。相关研究 [<xref ref-type="bibr" rid="hanspub.40888-ref14">14</xref>] 发现在从胃黏膜正常组织到癌前病变再到胃癌疾病进展进程，P16甲基化阳性率明显呈现出递增表现，并且在胃癌发生淋巴结转移的P16基因甲基化阳性率明显较高，可见P16在胃癌的进展以及转移中均起到作用，可作为胃癌诊断的重要标志物。Peng等 [<xref ref-type="bibr" rid="hanspub.40888-ref15">15</xref>] 研究发现，P16基因启动子甲基化是诊断胃癌的一种有用的方法，其灵敏度相对较低，但特异性很高。Wu等 [<xref ref-type="bibr" rid="hanspub.40888-ref13">13</xref>] 研究发现，胃癌p16甲基化率(85.9%; 79/92)显著高于其癌旁正常组织(12.0%; 11/92) (P &lt; 0.0001)。其甲基化和淋巴转移、腹膜转移、TNM分期等密切相关(P &lt; 0.05)。肿瘤组织P16甲基化程度升高的患者生存率低于P16甲基化程度不高患者(P = 0.042)。可见血清P16甲基化为评估胃癌发生发展以及预后不错的标志物。Lim等 [<xref ref-type="bibr" rid="hanspub.40888-ref16">16</xref>] 研究发现，P16甲基化诱导P16沉默，从而加速细胞周期，增加S期细胞数量，进而使得癌细胞容易吸收5-FU进入S期细胞，可明显提高药效。</p><p>人类RUNT相关转录因子3 (Runt-related transcription factor3, RUNX3)基因：位于染色体1p36.1区，一种肿瘤抑制基因。主要参与转化生长因子-β (TGF-β)转导通路调节，对TGF-β上皮细胞生长等起到负性调节作用。一旦RUNX3失活则会引起肿瘤发生。Wen等 [<xref ref-type="bibr" rid="hanspub.40888-ref17">17</xref>] 研究发现RUNX3甲基化对胃癌具有良好的诊断能力，其敏感性为63.2%，特异性为97.5%，RUNX3基因的启动子甲基化可能是临床实践中检测和诊断血液样本中胃癌的有力和潜在的无创生物标志物。SAKAKURA等 [<xref ref-type="bibr" rid="hanspub.40888-ref18">18</xref>] 研究发现，在胃癌病人外周循环检测出高水平甲基化RUNX3序列，RUNX3甲基化指数和肿瘤分期、组织学、淋巴管和脉管浸润等指标一致，比癌胚抗原更敏感。手术切除后血清RUNX3甲基化指数中位数明显减少。表明了外周血RUNX3甲基化监测在胃癌治疗后的临床价值和有效性。</p><p>E-钙黏蛋白1 (E-cadherin-1, CDH1)基因：位于16号染色体的基因，负责编码E-钙黏蛋白。该基因的编码蛋白是维持上皮细胞间黏附的主要蛋白，一种通过钙离子介导细胞间黏连的跨膜蛋白。若该基因发生突变，可使肿瘤增殖、侵袭、浸润、转移加剧。Kim等 [<xref ref-type="bibr" rid="hanspub.40888-ref19">19</xref>] 研究发现，CDH1甲基化为胃癌发病常见早期事件，和E-cadherin表达下调显著相关，可能和早期胃癌的转移有关，并在分化中发挥重要作用。Yu等 [<xref ref-type="bibr" rid="hanspub.40888-ref20">20</xref>] 研究发现，92例(81.5%)胃癌组织，其中75例(81.5%)均发现CDH1甲基化，和肿瘤的大小、生长模式、分化、浸润深度、淋巴结转移、和TNM分期均显著关联(均P &lt; 0.05)。术前腹腔冲洗中，有或没有CDH1甲基化患者其生存率存在显著性差异。结果表明术前腹腔冲洗中CDH1甲基化为胃癌病人独立危险因素。</p><p>人类同源突变体1 (human Mut L homolog1, hMLH1)基因：一种碱基错配修复基因。参与维持基因组稳定，在多种组织均有表达。其出现功能缺失后，可出现染色体和微卫星不稳定，导致肿瘤发生。高甲基化的hMLH1通过调节 hMLH1蛋白而导致胃癌。Shen等 [<xref ref-type="bibr" rid="hanspub.40888-ref21">21</xref>] 研究发现，hMLH1甲基化是预测胃癌的生物标志物，但可能不会影响胃癌行为。Li等 [<xref ref-type="bibr" rid="hanspub.40888-ref22">22</xref>] 研究发现，胃癌患者MLH1甲基化与奥沙利铂耐药有关。Shigeyasu等 [<xref ref-type="bibr" rid="hanspub.40888-ref23">23</xref>] 研究表明，MLH1甲基化状态可能是胃癌患者预后标志物。</p></sec></sec><sec id="s7"><title>3. DNA甲基化在胃癌诊疗中的应用</title><sec id="s7_1"><title>3.1. 早期诊断</title><p>目前胃癌确诊主要依赖于胃镜检查以及活检组织病理检查，而胃镜检查水准的高低主要取决于胃镜医师的主观判断(即个人专业水平)，存在较大的差异性。无痛胃镜检查花费较大，而普通胃镜检查对于大多数被检者来讲十分痛苦，为有创性操作，并有侵入性检查发生相关并发症的风险。故寻求一种患者痛苦与风险相对较小且更为有效的早期诊断的检查手段显得极为迫切，而DNA甲基化的研究使得在活体组织标本以及相关体液(血清、胃液等)中检测DNA甲基化以作为诊断胃癌的新方法成为了可能的突破点。</p><p>胃癌患者体内的胃癌细胞可以释放循环核酸到血液中，而通过对于血液中循环核酸的DNA (即循环肿瘤DNA，circulating tumour DNA，ctDNA)进行甲基化检测，能用来进行胃癌早期筛查与诊断。有微创、实时、反映整个机体状态等优点，而非单一组织。有研究 [<xref ref-type="bibr" rid="hanspub.40888-ref24">24</xref>] 表明血液和胃癌组织CDX2甲基化水平一致。胃液中的细胞容易被胃液侵蚀，导致于胃液中检查相关细胞的基因甲基化灵敏度较差，此方法仍然有待于今后进一步深入的研究，但它仍然为在体液检测相关基因甲基化来确诊胃癌提供新的可能。Liu等 [<xref ref-type="bibr" rid="hanspub.40888-ref25">25</xref>] 研究发现，Reprimo和hMLH1发生DNA甲基化，抑制了蛋白质表达，并参与胃癌发病和进展。血清Reprimo和hMLH1DNA甲基化水平联合测定对早期诊断胃癌具有重要的意义。Pimson等 [<xref ref-type="bibr" rid="hanspub.40888-ref26">26</xref>] 研究发现，血液样本中PCDH10与RASSF1A甲基化可作为胃癌血液中潜在无创性诊断指标。Wang等 [<xref ref-type="bibr" rid="hanspub.40888-ref27">27</xref>] 研究发现，血清FLNC、THBS1、UCHL1和DLEC1的启动子甲基化程度可以判断胃癌的存在，血清中UCHL1也和胃癌肿瘤分期和淋巴结转移显著关联，可反映预后不良。Wen等 [<xref ref-type="bibr" rid="hanspub.40888-ref17">17</xref>] 研究发现，RUNX3、RASS F1A和Reprimo启动子甲基化对胃癌与非肿瘤对照的血液样本具有良好的诊断能力，(RUNX3：敏感性为63.2%，特异性为97.5%；RASS F1A：敏感性为61.5%，特异性为96.3%；Reprimo：敏感性为82.0%，特异性为89.0%)，表明RUNX3、RASSF1A和Reprimo基因的启动子甲基化可能是临床实践中检测和诊断血液样本中胃癌的有力和潜在的无创生物标志物，特别是Reprimo基因。Hu等 [<xref ref-type="bibr" rid="hanspub.40888-ref28">28</xref>] 研究发现，血样DNA甲基化检测胃癌的特异性高，敏感性适中，多个甲基化基因的检测或血浆样本的检测可明显提高诊断的敏感性。Lin等 [<xref ref-type="bibr" rid="hanspub.40888-ref29">29</xref>] 研究发现，联合检测ZIC1、HOXD10和RUNX3启动子高甲基化可能是早期检测胃癌和癌前病变的一种很有前途的策略。Wang等 [<xref ref-type="bibr" rid="hanspub.40888-ref30">30</xref>] 研究发现，胃癌组织(69.4%, 34/49)和癌周组织(53.3%, 16/30)的ECRG4启动子甲基化率高于正常组织(6.7%, 1/15) (P &lt; 0.01)，第III、IV期(80%, 24/30) ECRG4启动子甲基化率高于第I、II期胃癌组织(52.6%, 10/19) (P &lt; 0.05)。异常ECRG4启动子甲基化能用做早期胃癌监测与病理分期预测。并且ECRG4可能会作为胃癌的治疗靶点。Pirini等 [<xref ref-type="bibr" rid="hanspub.40888-ref31">31</xref>] 研究发现，IRF4、ELMO1、CLIP4与MSC启动子甲基化结合全球DNA甲基化指数(GDMI) &gt; 4是内镜活检中胃癌风险分层的有用分子工具。Oishi等 [<xref ref-type="bibr" rid="hanspub.40888-ref32">32</xref>] 研究发现，在早期胃癌患者中，Sox17在治疗前和治疗后甲基化之间有着显著差异(P &lt; 0.0001)，可用于早期胃癌患者治疗术后复发早期检测。目前关于DNA甲基化与胃癌早期诊断的研究很多，但其具体应用到一线临床中仍需要进一步的研究探索与实践。</p></sec><sec id="s7_2"><title>3.2. 药物治疗</title><p>胃癌治疗方面目前主要有内镜以及手术治疗、化疗等。目前研究认为肿瘤发病过程基因异常甲基化和DNMT高表达有关，而抑制DNMT成为治疗肿瘤的一种具有巨大潜力的治疗手段。DNA甲基化抑制剂可解除不表达或表达下降的抑癌基因使其恢复常规功能，恢复正常细胞周期与信号转导通路等 [<xref ref-type="bibr" rid="hanspub.40888-ref33">33</xref>]，故为攻克肿瘤提供新的选择。DNA甲基化抑制剂分为核苷类(5-氮杂胞苷和5-氮杂-2'-脱氧胞苷(地西他滨)为代表)、非核苷类(生物类黄酮、染料木黄酮等)。其已经在MDS和其他血液系统肿瘤中进行了广泛的临床应用，效果明显 [<xref ref-type="bibr" rid="hanspub.40888-ref34">34</xref>]。可能在其他恶性肿瘤中同样具有治疗潜力，已有研究 [<xref ref-type="bibr" rid="hanspub.40888-ref35">35</xref>] 认为胃癌治疗中同样有一定潜力。Yang等 [<xref ref-type="bibr" rid="hanspub.40888-ref36">36</xref>] 研究发现，蔓荆子黄素30 &#181;mol/l降低了RECK启动子甲基化水平31%，1、10和30 &#181;mol/l蔓荆子黄素处理可显著提高RECK蛋白表达和mRNA水平(P均 &lt; 0.05)，并且发现蔓荆子黄素下调了DNMT1的mRNA水平和蛋白表达。DNA结合试验表明蔓荆子黄素降低了Sp1的DNA结合活性，对Sp1的抑制可能导致DNMT1的活性降低，对甲基化产生抑制作用，并影响了肿瘤细胞的细胞周期，使得MGC803细胞的增殖受到了抑制。故该研究表明蔓荆子黄素通过降低甲基化程度与上调RECK表达来抑制MGC-803细胞增殖。由于其来源于天然植物，毒性相对较低。在脱氧胞苷等作用不大的情况下，蔓荆子黄素可能有更广泛的应用。作为一种去甲基化药物，由于其不良反应较少，可能成为胃癌的一种新的干预手段。传统化疗和DNMT抑制剂联合时可以提供化疗敏感度，地西他滨通过去甲基化活性可引起TFAP2E反应性表达，这一特性可能有助于增强肿瘤细胞对5-FU敏感度 [<xref ref-type="bibr" rid="hanspub.40888-ref37">37</xref>]。然而去甲基化可以预防某些癌症同时，但也可能会导致遗传不稳定性，升高其他肿瘤发病风险 [<xref ref-type="bibr" rid="hanspub.40888-ref7">7</xref>]。研究发现DNA甲基化还和胃癌化疗效果评估有着密切联系。Sugita等 [<xref ref-type="bibr" rid="hanspub.40888-ref38">38</xref>] 研究发现，原发胃癌手术切除后接受以氟嘧啶为基础的化疗，以治疗远处转移或复发，有DAPK或BNIP3甲基化或者两者都有甲基化病人应答率明显比无甲基化病人低(P = 0.003)。发现DAPK或BNIP3甲基化降低了该化疗方案对胃癌病人的敏感性，BNIP3和DAPK的甲基化可预测胃癌化疗反应降低和预后不良。</p></sec><sec id="s7_3"><title>3.3. 评估预后</title><p>研究 [<xref ref-type="bibr" rid="hanspub.40888-ref39">39</xref>] 表明相关基因甲基化的程度和肿瘤的大小、浸润程度、淋巴结转移等有着密切关系。DNA可通过基因甲基化来评估胃癌患者的预后，其相关DNA甲基化水平的高低可以判断胃癌患者病情程度以及评估预后 [<xref ref-type="bibr" rid="hanspub.40888-ref40">40</xref>]。Yang等 [<xref ref-type="bibr" rid="hanspub.40888-ref41">41</xref>] 研究发现，GDF1高甲基化和胃癌患者生存不良显著关联。Yuan等 [<xref ref-type="bibr" rid="hanspub.40888-ref42">42</xref>] 研究发现，肿瘤组织中miR-106a水平(2.700 &#177; 2.565)明显高于邻近组织(1.321 &#177; 0.904) (P &lt; 0.05)。此外，胃癌血浆miR-106a表达水平(9.479 &#177; 5.595)与健康组(2.594 &#177; 2.329)相比显著上调(P &lt; 0.05)，而胃切除术后胃癌患者血浆中miR-106a的表达明显下降。进一步统计数据表明，高miR-106a表达和胃癌淋巴转移程度以及TNM分期密切关联。应用ROC曲线来评估miR-106a作为胃癌患者诊断标记，结果表明，组织标本的敏感性和特异性分别为60.4%、68.2%，血浆标本敏感性与特异性分别是72.9%、63.6。最后，对28个配对胃癌组织miR-106a甲基化情况进行了探讨，结果表明，甲基化率在癌症组织中为53.6%，在邻近组织中为85.7%。此外，结果还表明，miR-106a启动子低甲基化与其高表达有关。故miR-106a可能成为进展性胃癌潜在预后标志物，并通过启动子低甲基化上调循环miR-106a，可作为胃癌的候选诊断和预后指标。有研究 [<xref ref-type="bibr" rid="hanspub.40888-ref43">43</xref>] 表明在胃癌中，LINE-1低甲基化与较短生存时间有关，LINE-1甲基化状态可能为晚期胃癌标志，也为独立于癌症分期预后指标，有助于识别预后不良胃癌患者。Hu等 [<xref ref-type="bibr" rid="hanspub.40888-ref44">44</xref>] 研究发现，CLDN11、APOD和CHRDL1与CLIP4DNA甲基化和胃癌风险评估显著相关，被确定为潜在的预后生物标志物。Xu等 [<xref ref-type="bibr" rid="hanspub.40888-ref45">45</xref>] 研究发现，SOX11高甲基化和不良预后密切关联，可作为独立生存指标。Wang等 [<xref ref-type="bibr" rid="hanspub.40888-ref5">5</xref>] 研究发现，MDGA2高甲基化病人生存率显著降低(P = 0.005)。Kaplan-Meier生存曲线表明，MDGA2甲基化与早期胃癌患者存活时间降低有显著关系。MDGA2为胃癌进展过程关键抑癌因子，其高甲基化为胃癌病人独立预后因素。Sui等 [<xref ref-type="bibr" rid="hanspub.40888-ref46">46</xref>] 研究发现，异常DNA甲基化为HOXB13mRNA表达下调关键因素，HOXB13mRNA表达下降和胃癌的分化、浸润程度、转移和TNM分期等相关，是胃癌患者预后不良的显著因素。Harada等 [<xref ref-type="bibr" rid="hanspub.40888-ref47">47</xref>] 研究发现，高CDO1甲基化胃癌病人预后明显低于低CDO1甲基化病人(P &lt; 0.0001)。COX比例风险模型确定高CDO1甲基化(P = 0.033)为独立预后因素。该研究对CDO1基因的启动子DNA高甲基化进行了严格的验证，认为它是原发性胃癌特定阶段预后的重要生物标志物。Deng等 [<xref ref-type="bibr" rid="hanspub.40888-ref48">48</xref>] 研究定量检测了459例胃癌患者BCL6B启动子CPG位点甲基化情况，在BCL6B存在多个甲基化位点的患者和生存不良明显相关。此外，利用Akaike信息标准值计算，发现BCL6B启动子甲基化计数是胃癌患者最佳预后预测指标。Wu等 [<xref ref-type="bibr" rid="hanspub.40888-ref49">49</xref>] 研究发现，原发肿瘤大小和淋巴结转移被确定为胃癌患者ASC/TMS1甲基化水平独立相关因素，多因素分析表明，ASC/TMS1甲基化和分化程度、浆膜浸润、转移是胃癌的独立预后标志物，Cox回归与Akaike信息准则值计算可知，淋巴结转移和ASC/TMS1启动子甲基化状态是胃癌患者的最佳预后预测指标。ASC/TMS1甲基化状态对临床评估胃癌预后具有潜在适用性。Zhang等 [<xref ref-type="bibr" rid="hanspub.40888-ref50">50</xref>] 研究发现，TRAF2在胃癌患者中的表达通过DNA低甲基化而增加，这种甲基化可能是胃癌中一个独立的诊断和预后指标。进一步研究TRAF2甲基化预后价值，Kaplan-Meier表明，TRAF2低甲基化患者寿命比TRAF2高甲基化患者短得多(P &lt; 0.001)。Cox回归分析显示TRAF2低甲基化(P = 0.001)、淋巴结转移(P = 0.002)、远处转移(P = 0.030)、分化(P = 0.009)均为胃癌的重要预后因素。结果表明TRAF2在胃癌患者中的表达通过DNA低甲基化而增加，这种甲基化可能是胃癌中一个独立的预后指标。</p></sec></sec><sec id="s8"><title>4. 总结与展望</title><p>DNA甲基化在胃癌演变进程有着重要作用，其在胃癌发病机制中作用的相关研究对胃癌早期诊断、治疗以及判断预后有着深远意义，可能会对未来人类攻克胃癌做出巨大的贡献，甚至可能会对其他肿瘤的攻克也发挥作用。然而DNA甲基化在胃癌进展过程中的详细作用机制及在其早期检测、治疗、评估预后等方面的精准方案仍然存在诸多空白与争议，仍有待我们进一步进行研究与探索。</p></sec><sec id="s9"><title>基金项目</title><p>山东省临沂市人民医院研究生培养基金项目(YJS2020009)。</p></sec><sec id="s10"><title>文章引用</title><p>孙良旭,郭安兵,张艳青,彭利军. DNA甲基化与胃癌关系的研究进展Research Progress on the Relationship between DNA Methylation and Gastric Cancer[J]. 临床医学进展, 2021, 11(03): 965-973. https://doi.org/10.12677/ACM.2021.113139</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.40888-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424.  
&lt;br&gt;https://doi.org/10.3322/caac.21492</mixed-citation></ref><ref id="hanspub.40888-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Rodriguez-Paredes, M. and Esteller, M. (2011) Cancer Epigenetics Reaches Mainstream Oncology. Nature Medicine, 17, 330-339. &lt;br&gt;https://doi.org/10.1038/nm.2305</mixed-citation></ref><ref id="hanspub.40888-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Jin, Z. and Liu, Y. (2018) DNA Methylation in Human Diseases. Genes and Diseases, 5, 1-8.  
&lt;br&gt;https://doi.org/10.1016/j.gendis.2018.01.002</mixed-citation></ref><ref id="hanspub.40888-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Hu, X.T. and He, C. (2013) Recent Progress in the Study of Methylated Tumor Suppressor Genes in Gastric Cancer. Chinese Journal of Cancer, 32, 31-41. &lt;br&gt;https://doi.org/10.5732/cjc.011.10175</mixed-citation></ref><ref id="hanspub.40888-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Wang, K., Liang, Q., Li, X., et al. (2016) MDGA2 Is a Novel Tumour Suppressor Cooperating with DMAP1 in Gastric Cancer and Is Associated with Disease Outcome. Gut, 65, 1619-1631. &lt;br&gt;https://doi.org/10.1136/gutjnl-2015-309276</mixed-citation></ref><ref id="hanspub.40888-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Ehrlich, M. and Lacey, M. (2013) DNA Hypomethylation and Hemimethylation in Cancer. Advances in Experimental Medicine and Biology, 754, 31-56. &lt;br&gt;https://doi.org/10.1007/978-1-4419-9967-2_2</mixed-citation></ref><ref id="hanspub.40888-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Gaudet, F., Hodgson, J.G., Eden, A., et al. (2003) Induction of Tumors in Mice by Genomic Hypomethylation. Science, 300, 489-492. &lt;br&gt;https://doi.org/10.1126/science.1083558</mixed-citation></ref><ref id="hanspub.40888-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Leodolter, A., Alonso, S., Gonzalez, B., et al. (2015) Somatic DNA Hypomethylation in H. pylori-Associated High-Risk Gastritis and Gastric Cancer: Enhanced Somatic Hypomethylation Associates with Advanced Stage Cancer. Clinical and Translational Gastroenterology, 6, e85. &lt;br&gt;https://doi.org/10.1038/ctg.2015.14</mixed-citation></ref><ref id="hanspub.40888-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Yang, J., Wei, X., Wu, Q., et al. (2011) Clinical Significance of the Expression of DNA Methyltransferase Proteins in Gastric Cancer. Molecular Medicine Reports, 4, 1139-1143.</mixed-citation></ref><ref id="hanspub.40888-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Yang, X.X., He, X.Q., Li, F.X., et al. (2012) Risk-Association of DNA Methyltransferases Polymorphisms with Gastric Cancer in the Southern Chinese Population. International Journal of Molecular Sciences, 13, 8364-8378.  
&lt;br&gt;https://doi.org/10.3390/ijms13078364</mixed-citation></ref><ref id="hanspub.40888-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Jurkowska, R.Z., Jurkowski, T.P. and Jeltsch, A. (2011) Structure and Function of Mammalian DNA Methyltransferases. Chembiochem, 12, 206-222. &lt;br&gt;https://doi.org/10.1002/cbic.201000195</mixed-citation></ref><ref id="hanspub.40888-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Jobe, E.M., Gao, Y., Eisinger, B.E., et al. (2017) Methyl-CpG-Binding Protein MBD1 Regulates Neuronal Lineage Commitment through Maintaining Adult Neural Stem Cell Identity. Journal of Neuroscience, 37, 523-536.  
&lt;br&gt;https://doi.org/10.1523/JNEUROSCI.1075-16.2016</mixed-citation></ref><ref id="hanspub.40888-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Wu, Y.C., Lv, P., Han, J., et al. (2014) Enhanced Serum Methylated p16 DNAs Is Associated with the Progression of Gastric Cancer. International Journal of Clinical and Experimental Pathology, 7, 1553-1562.</mixed-citation></ref><ref id="hanspub.40888-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">白艳丽, 金建军, 刘献民, 等. 胃癌p16基因启动子区甲基化状态的研究[J]. 中国实用医药, 2016, 11(14): 56-57.</mixed-citation></ref><ref id="hanspub.40888-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Peng, D., Zhang, H. and Sun, G. (2014) The Relationship between P16 Gene Promoter Methylation and Gastric Cancer: A Meta-Analysis Based on Chinese Patients. Journal of Cancer Research and Therapeutics, 10, 292-295.  
&lt;br&gt;https://doi.org/10.4103/0973-1482.151535</mixed-citation></ref><ref id="hanspub.40888-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Lim, H.K., Park, J.M., Chi, K.C., et al. (2013) Disappearance of Serum Methylated p16 Indicates Longer Survival in Patients with Gastric Cancer. Journal of Gastric Cancer, 13, 157-163. &lt;br&gt;https://doi.org/10.5230/jgc.2013.13.3.157</mixed-citation></ref><ref id="hanspub.40888-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Wen, J., Zheng, T., Hu, K., et al. (2017) Promoter Methylation of Tumor-Related Genes as a Potential Biomarker Using Blood Samples for Gastric Cancer Detection. Oncotarget, 8, 77783-77793.  
&lt;br&gt;https://doi.org/10.18632/oncotarget.20782</mixed-citation></ref><ref id="hanspub.40888-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Sakakura, C., Hamada, T., Miyagawa, K., et al. (2009) Quantitative Analysis of Tumor-Derived Methylated RUNX3 Sequences in the Serum of Gastric Cancer Patients. Anticancer Research, 29, 2619-2625.</mixed-citation></ref><ref id="hanspub.40888-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Yi, K.D., Kyoon, J.J., Kyu, P.Y., et al. (2007) E-Cadherin Expression in Early Gastric Carcinoma and Correlation with Lymph Node Metastasis. Journal of Surgical Oncology, 96, 429-435. &lt;br&gt;https://doi.org/10.1002/jso.20732</mixed-citation></ref><ref id="hanspub.40888-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Yu, Q.M., Wang, X.B., Luo, J., et al. (2012) CDH1 Methylation in Preoperative Peritoneal Washes Is an Independent Prognostic Factor for Gastric Cancer. Journal of Surgical Oncology, 106, 765-771. &lt;br&gt;https://doi.org/10.1002/jso.23116</mixed-citation></ref><ref id="hanspub.40888-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Shen, S., Chen, X., Li, H., et al. (2018) MLH1 Promoter Methylation and Prediction/Prognosis of Gastric Cancer: A Systematic Review and Meta and Bioinformatic Analysis. Journal of Cancer, 9, 1932-1942.  
&lt;br&gt;https://doi.org/10.7150/jca.23284</mixed-citation></ref><ref id="hanspub.40888-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Li, Y., Yang, Y., Lu, Y., et al. (2015) Predictive Value of CHFR and MLH1 Methylation in Human Gastric Cancer. Gastric Cancer, 18, 280-287. &lt;br&gt;https://doi.org/10.1007/s10120-014-0370-2</mixed-citation></ref><ref id="hanspub.40888-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Shigeyasu, K., Nagasaka, T., Mori, Y., et al. (2015) Clinical Significance of MLH1 Methylation and CpG Island Methylator Phenotype as Prognostic Markers in Patients with Gastric Cancer. PLoS ONE, 10, e130409.  
&lt;br&gt;https://doi.org/10.1371/journal.pone.0130409</mixed-citation></ref><ref id="hanspub.40888-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">蒋伟, 张健锋, 毛振彪. 胃癌组织及外周血中CDX2基因甲基化的关系及其临床意义[J]. 交通医学, 2015, 29(4): 329-332.</mixed-citation></ref><ref id="hanspub.40888-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Liu, L. and Yang, X. (2015) Implication of Reprimo and hMLH1 Gene Methylation in Early Diagnosis of Gastric Carcinoma. International Journal of Clinical and Experimental Pathology, 8, 14977-14982.</mixed-citation></ref><ref id="hanspub.40888-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Pimson, C., Ekalaksananan, T., Pientong, C., et al. (2016) Aberrant Methylation of PCDH10 and RASSF1A Genes in Blood Samples for Non-Invasive Diagnosis and Prognostic Assessment of Gastric Cancer. PeerJ, 4, e2112.  
&lt;br&gt;https://doi.org/10.7717/peerj.2112</mixed-citation></ref><ref id="hanspub.40888-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Wang, G., Zhang, W., Zhou, B., et al. (2015) The Diagnosis Value of Promoter Methylation of UCHL1 in the Serum for Progression of Gastric Cancer. BioMed Research International, 2015, Article ID: 741030.  
&lt;br&gt;https://doi.org/10.1155/2015/741030</mixed-citation></ref><ref id="hanspub.40888-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Hu, W., Zheng, W., Liu, Q., et al. (2017) Diagnostic Accuracy of DNA Methylation in Detection of Gastric Cancer: A Meta-Analysis. Oncotarget, 8, 113142-113152. &lt;br&gt;https://doi.org/10.18632/oncotarget.22613</mixed-citation></ref><ref id="hanspub.40888-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Lin, Z., Luo, M., Chen, X., et al. (2017) Combined Detection of Plasma ZIC1, HOXD10 and RUNX3 Methylation Is a Promising Strategy for Early Detection of Gastric Cancer and Precancerous Lesions. Journal of Cancer, 8, 1038-1044.  
&lt;br&gt;https://doi.org/10.7150/jca.18169</mixed-citation></ref><ref id="hanspub.40888-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Wang, Y.B. and Ba, C.F. (2012) Promoter Methylation of Esophageal Cancer-Related Gene 4 in Gastric Cancer Tissue and Its Clinical Significance. Hepatogastroenterology, 59, 1696-1698.</mixed-citation></ref><ref id="hanspub.40888-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Pirini, F., Noazin, S., Jahuira-Arias, M.H., et al. (2017) Early Detection of Gastric Cancer Using Global, Genome-Wide and IRF4, ELMO1, CLIP4 and MSC DNA Methylation in Endoscopic Biopsies. Oncotarget, 8, 38501-38516.  
&lt;br&gt;https://doi.org/10.18632/oncotarget.16258</mixed-citation></ref><ref id="hanspub.40888-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Oishi, Y., Watanabe, Y., Yoshida, Y., et al. (2012) Hypermethylation of Sox17 Gene Is Useful as a Molecular Diagnostic Application in Early Gastric Cancer. Tumor Biology, 33, 383-393. &lt;br&gt;https://doi.org/10.1007/s13277-011-0278-y</mixed-citation></ref><ref id="hanspub.40888-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Baylin, S.B. (2005) DNA Methylation and Gene Silencing in Cancer. Nature Clinical Practice Oncology, 2, S4-S11.  
&lt;br&gt;https://doi.org/10.1038/ncponc0354</mixed-citation></ref><ref id="hanspub.40888-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Piekarz, R.L. and Bates, S.E. (2009) Epigenetic Modifiers: Basic Understanding and Clinical Development. Clinical Cancer Research, 15, 3918-3926. &lt;br&gt;https://doi.org/10.1158/1078-0432.CCR-08-2788</mixed-citation></ref><ref id="hanspub.40888-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Deng, P., Chang, X.J., Gao, Z.M., et al. (2018) Downregulation and DNA Methylation of ECRG4 in Gastric Cancer. OncoTargets and Therapy, 11, 4019-4028. &lt;br&gt;https://doi.org/10.2147/OTT.S161200</mixed-citation></ref><ref id="hanspub.40888-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Yang, F., He, K., Huang, L., et al. (2017) Casticin Inhibits the Activity of Transcription Factor Sp1 and the Methylation of RECK in MGC803 Gastric Cancer Cells. Experimental and Therapeutic Medicine, 13, 745-750.  
&lt;br&gt;https://doi.org/10.3892/etm.2016.4003</mixed-citation></ref><ref id="hanspub.40888-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Wu, F.L., Li, R.T., Yang, M., et al. (2015) Gelatinases-Stimuli Nanoparticles Encapsulating 5-Fluorouridine and 5-Aza-2’-deoxycytidine Enhance the Sensitivity of Gastric Cancer Cells to Chemical Therapeutics. Cancer Letters, 363, 7-16. &lt;br&gt;https://doi.org/10.1016/j.canlet.2015.01.006</mixed-citation></ref><ref id="hanspub.40888-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Sugita, H., Iida, S., Inokuchi, M., et al. (2011) Methylation of BNIP3 and DAPK Indicates Lower Response to Chemotherapy and Poor Prognosis in Gastric Cancer. Oncology Reports, 25, 513-518.  
&lt;br&gt;https://doi.org/10.3892/or.2010.1085</mixed-citation></ref><ref id="hanspub.40888-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Joo, J.K., Kim, S.H., Kim, H.G., et al. (2010) CpG Methylation of Transcription Factor 4 in Gastric Carcinoma. Annals of Surgical Oncology, 17, 3344-3353. &lt;br&gt;https://doi.org/10.1245/s10434-010-1131-z</mixed-citation></ref><ref id="hanspub.40888-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Oh, J.H., Jung, S.H., Hong, S.J., et al. (2015) DNA Methylation as Surrogate Marker for Gastric Cancer. Journal of Cancer Prevention, 20, 172-178. &lt;br&gt;https://doi.org/10.15430/JCP.2015.20.3.172</mixed-citation></ref><ref id="hanspub.40888-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Yang, W., Mok, M.T., Li, M.S., et al. (2016) Epigenetic Silencing of GDF1 Disrupts SMAD Signaling to Reinforce Gastric Cancer Development. Oncogene, 35, 2133-2144. &lt;br&gt;https://doi.org/10.1038/onc.2015.276</mixed-citation></ref><ref id="hanspub.40888-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Yuan, R., Wang, G., Xu, Z., et al. (2016) Up-Regulated Circulating miR-106a by DNA Methylation Promised a Potential Diagnostic and Prognostic Marker for Gastric Cancer. Anti-Cancer Agents in Medicinal Chemistry, 16, 1093-1100.  
&lt;br&gt;https://doi.org/10.2174/1871520615666150716110657</mixed-citation></ref><ref id="hanspub.40888-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Shigaki, H., Baba, Y., Watanabe, M., et al. (2013) LINE-1 Hypomethylation in Gastric Cancer, Detected by Bisulfite Pyrosequencing, Is Associated with Poor Prognosis. Gastric Cancer, 16, 480-487.  
&lt;br&gt;https://doi.org/10.1007/s10120-012-0209-7</mixed-citation></ref><ref id="hanspub.40888-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Hu, C., Zhou, Y., Liu, C., et al. (2018) A Novel Scoring System for Gastric Cancer Risk Assessment Based on the Expression of Three CLIP4 DNA Methylation-Associated Genes. International Journal of Oncology, 53, 633-643.  
&lt;br&gt;https://doi.org/10.3892/ijo.2018.4433</mixed-citation></ref><ref id="hanspub.40888-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">Xu, X., Chang, X., Li, Z., et al. (2015) Aberrant SOX11 Promoter Methylation Is Associated with Poor Prognosis in Gastric Cancer. Cellular Oncology, 38, 183-194. &lt;br&gt;https://doi.org/10.1007/s13402-015-0219-7</mixed-citation></ref><ref id="hanspub.40888-ref46"><label>46</label><mixed-citation publication-type="other" xlink:type="simple">Sui, B.Q., Zhang, C.D., Liu, J.C., et al. (2018) HOXB13 Expression and Promoter Methylation as a Candidate Biomarker in Gastric Cancer. Oncology Letters, 15, 8833-8840. &lt;br&gt;https://doi.org/10.3892/ol.2018.8371</mixed-citation></ref><ref id="hanspub.40888-ref47"><label>47</label><mixed-citation publication-type="other" xlink:type="simple">Harada, H., Hosoda, K., Moriya, H., et al. (2019) Cancer-Specific Promoter DNA Methylation of Cysteine Dioxygenase Type 1 (CDO1) Gene as an Important Prognostic Biomarker of Gastric Cancer. PLoS ONE, 14, e214872.  
&lt;br&gt;https://doi.org/10.1371/journal.pone.0214872</mixed-citation></ref><ref id="hanspub.40888-ref48"><label>48</label><mixed-citation publication-type="other" xlink:type="simple">Deng, J., Liang, H., Dong, Q., et al. (2014) The Survival Decrease in Gastric Cancer Is Associated with the Methylation of B-Cell CLL/Lymphoma 6 Member B Promoter. Open Biology, 4, Article ID: 140067.  
&lt;br&gt;https://doi.org/10.1098/rsob.140067</mixed-citation></ref><ref id="hanspub.40888-ref49"><label>49</label><mixed-citation publication-type="other" xlink:type="simple">Wu, L., Zhang, C., Wang, X., et al. (2016) Methylation of ASC/TMS1 Promoter Is Associated with Poor Prognosis of Patients with Gastric Cancer. Clinical and Translational Oncology, 18, 296-303.  
&lt;br&gt;https://doi.org/10.1007/s12094-015-1367-y</mixed-citation></ref><ref id="hanspub.40888-ref50"><label>50</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, J., Dai, W. and Yang, X. (2015) Methylation Status of TRAF2 Is Associated with the Diagnosis and Prognosis of Gastric Cancer. International Journal of Clinical and Experimental Pathology, 8, 14228-14234.</mixed-citation></ref></ref-list></back></article>